MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)
about
A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology.Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapThe evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients.Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: Decoy, trap and kill chRecombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.Genetic and metabolic comparison of orthotopic and heterotopic patient-derived pancreatic-cancer xenografts to the original patient tumors.Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model
P2860
Q42139483-A054C34D-901C-4DFA-B87C-AE1DABAEE0F0Q46023921-C0FFFB63-8A21-4284-A3E1-11D26C4241B4Q47105755-02FFE36C-907B-4906-8EB0-8E72349BF470Q48098689-C3201981-B047-4C07-838B-2E38E20342DCQ48135854-53BE2F7D-6855-4D5E-9D29-151FB93D2C93Q48156221-E0A09862-224E-4715-96D8-A9550F00D259Q49185022-C96CB9E5-55F0-4F2A-91A3-3440441F4079Q50353132-50C78A21-53E4-4A46-9B29-7D458F94F839Q58736789-A2A7BD32-E5F7-4ABA-A8B1-D0692D9F4A1E
P2860
MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
MEK inhibitors cobimetinib and ...... ed orthotopic xenograft (PDOX)
@en
type
label
MEK inhibitors cobimetinib and ...... ed orthotopic xenograft (PDOX)
@en
prefLabel
MEK inhibitors cobimetinib and ...... ed orthotopic xenograft (PDOX)
@en
P2093
P2860
P50
P356
P1433
P1476
MEK inhibitors cobimetinib and ...... ed orthotopic xenograft (PDOX)
@en
P2093
Bryan M Clary
Jonathan C Delong
Kei Kawaguchi
Michael Bouvet
Michiaki Unno
Robert M Hoffman
Tasuku Kiyuna
Thinzar M Lwin
P2860
P304
47490-47496
P356
10.18632/ONCOTARGET.17667
P407
P577
2017-07-01T00:00:00Z